Genpharmasec Posts Strong Turnaround: Q2 Revenue Up 162%

Revenue surged to Rs 85.66 crore from Rs 32.64 crore; Net profit hit Rs 1.03 crore.

Reader Takeaway: Strong revenue growth and profit turnaround mark a positive quarter, tempered by upcoming subsidiary divestment and management exits.

What just happened

Genpharmasec Ltd reported consolidated financial results for the quarter ended September 30, 2026. The company saw a massive 162.4% jump in consolidated revenue to Rs 85.66 crore compared to Rs 32.64 crore in the same period last year. Notably, the firm swung to a consolidated profit of Rs 1.03 crore from a loss of Rs 1.18 crore in Q2 of the previous fiscal year.

Why this matters

The financial shift represents a significant turnaround for the company. Alongside the performance boost, the board approved the divestment of its wholly-owned subsidiary, Clinigenome India Private Limited, to Micro Genomics India Private Limited. The transaction is expected to conclude on or before March 31, 2027. The company clarified that Clinigenome is not a material subsidiary.

Governance Update

Mr. Hardik Makwana, the Company Secretary and Compliance Officer, has resigned to pursue outside opportunities. His resignation is effective from the close of business hours on November 16, 2026. The departure of a key compliance official remains a point for investors to monitor regarding the transition process.

Risks to watch

While the financial trajectory is positive, investors should watch for the formal completion of the Clinigenome divestment by March 31, 2027. Additionally, the company must fill the vacant Company Secretary and Compliance Officer position to ensure ongoing regulatory adherence.

What to track next

Shareholders should track the official confirmation of the subsidiary sale completion and the subsequent appointment of a new Company Secretary to ensure leadership stability.